Asthma is a common obstructive lung disorder affecting more than 339 million people worldwide (
1). Approximately 8.3% of US children had asthma in 2017, which was lower than the rates in 2010 (9.4%) and 2001 (8.7%) (
2). However, asthma prevalence continues to increase in developing countries with an average of 13.14% (
3,
4). Numerous risk factors for asthma have been identified. The most well-documented risk factors include the patient’s gender, airway hyperreactivity, atopy, obesity, perinatal factors, exposure to allergens, infection, and tobacco smoke (
5). The successful management of asthma is based on regular monitoring of patients and their lung function, controlling environmental factors, and pharmacologic treatment. Inhalers have been identified as the cornerstone of asthma management and the safest and most effective way to treat and control asthma, as they reach the lungs directly (
6,
7). Broadly speaking, inhaler drugs (IDs) can be classified into four categories: Metered dose inhalers (MDIs), dry powder inhalers (DPIs), breath actuated inhalers (BAIs), and nebulizers (NBs) (
8). MDIs, the most commonly used inhaler devices, are propellant-based and deliver a specific amount of medication to the lungs in the form of an aerosol spray (
9). DPIs, the second type of inhalers, deliver asthma medication in a dry powder form.
New MDIs are BAIs, which depend on the inhalation starting to release the medication from the device (
10). Compared to the MDIs, DPIs are easier to use as they do not need propellants and coordination (
11). BAI, an advanced version of the MDIs technology, combines the advantages of MDIs and DPIs. The BAI senses the inhalation through an actuator and releases the medication automatically (
12). Furthermore, NBs convert the liquid form of medications into suitable aerosol droplets, which are best suited for inhalation. NBs do not require coordination and deliver the medication quickly and effectively to the lungs in the form of a mist. However, the wasted nebulized drugs are its most significant problem (
13). Despite new guidelines and treatment approaches, many asthma patients still do not achieve adequate asthma control (
14). The cause of the poorly controlled disease is mainly attributed to inadequate drug prescription, long-duration asthma, high airflow limitation, and inhaler mishandling (
14-
17). It is observed that most patients, even after proper training on how to use MDIs, still struggle to coordinate the proper usage (
18,
19). Since many upcoming non-traditional IDs are emerging, the healthcare provider’s responsibility is to educate patients on using each inhaler device correctly.